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ABSTRACT
Several host genetic factors play an important 
role in susceptibility to human immunodeficiency vi-
rus type 1 (HIV-1) infection and in its progression to 
acquired immune deficiency syndrome (AIDS). The 
interleukin-18 (IL-18) is a multifunctional proinflam-
matory cytokine that regulates immune responses and 
plays a pathogenic role in HIV-1 infection by enhanc-
ing viral replication. Single nucleotide polymorphisms 
(SNPs) in the IL-18 gene promoter region may lead to 
altered transcriptional activity and IL-18 production, 
and may account for variation in the risk of HIV-1 in-
fection. We have investigated the association between 
IL-18 promoter polymorphism −607C>A and HIV-1 
infection through a case-control study of 500 patients 
with HIV-1/AIDS and an equal number of age and sex 
matched controls in a north Indian population. Geno-
typing using sequence specific primer-polymerase 
chain reaction (SSP-PCR) showed a statistically sig-
nificant reduced risk of HIV-1 infection for the A>A 
genotype [odds ratio (OR) = 0.57, 95% confidence in-
terval (95% CI) = 0.33-0.98, p = 0.040], but not for the 
C>A genotype (OR = 0.87, 95% CI = 0.66-1.14, p = 
0.321). We concluded that the −607A allele of the IL-
18 gene promoter polymorphism may play a protective 
role against the progression of HIV-1 infection in this 
population.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) 
infection results in progressive deterioration of the im-
mune system and in acquired immune deficiency syn-
drome (AIDS). However, the rate at which the HIV-1 
infection progresses to AIDS varies considerably be-
tween individuals, some progressing rapidly after pri-
mary infection, while others remain asymptomatic with 
no evidence of immune dysfunction for over 15 years 
[1,2]. The reasons for the variation are multifactorial 
and may involve genetic, virological or immunological 
factors that function in different ways [3]. The role of 
host genetic variations has been intensively examined 
in different populations and in all major risk groups. 
These have revealed that genetic polymorphisms in 
genes for chemokine receptors or in those of their 
natural ligands are likely to influence susceptibility or 
resistance to HIV-1 infection as well as the subsequent 
rate of disease progression [3,4]. Genes for human 
leukocyte antigens (HLA) that regulate host immune 
response to infection have also been correlated with 
the clinical course of HIV-1 infection [5]. So far, in 
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addition to polymorphic variants in genes encoding for 
HIV-1 co-receptors and their ligands and those of HLA 
alleles, some T helper type 1 (Th1) and type 2 (Th2) 
cytokine genes have also been implicated to influence 
the rate of disease progression in HIV-1 seropositive 
patients either positively or negatively [6,7].
Cytokines play a crucial role in regulation of the 
balance between Th1 and Th2 immune responsiveness. 
The Th1 cytokines promote cell-mediated immunity to 
intracellular pathogens including viruses and other in-
tracellular pathogens, whereas Th2 cytokines enhance 
humoral immunity by up-regulating antibody produc-
tion against extracellular pathogens [8,9]. Furthermore, 
several cytokine related studies confirmed their key 
immunomodulatory role within the immune system 
and cytokine genes have been targeted for association 
studies of susceptibility and development of several 
immune-related and infectious diseases [10-13].
The interleukin-18 (IL-18) gene encoding human 
IL-18 cytokine is located at chromosome 11q22.2-
22.3 [14,15]. Three single nucleotide polymorphisms 
(SNPs) (–656G>T, –607C>A, –137G>C) within the 
IL-18 gene promoter have been localized. Of these, 
those at positions –137 and –607 influence the quan-
titative expression of the IL-18 protein. The –607C>A 
disrupts a potential cyclic adenosine monophosphate 
(cAMP) responsive element-binding protein (CREB) 
binding site and –137G>C abolishes the human histone 
4 transcription factor-1 (H4TF-1)-binding site , reduc-
ing its transcription. Thus, these two polymorphisms 
and their haplotypes seem to account for differential 
IL-18 expression and changes in the production of this 
cytokine [15].
The multiple biological functions of the IL-18 
gene are associated with a wide variety of allergic, 
inflammatory, autoimmune, cancerous and infectious 
diseases [16,17]. In the context of HIV-1 infection, the 
IL-18 cytokine also plays a pathogenic role by enhanc-
ing viral replication in monocytic cells and in T cells 
[18,19]. Moreover, clinical studies have demonstrated 
the involvement of IL-18 in the immunopathogenesis 
of HIV-1 infection [20-22]. However, most of these 
studies focused primarily on the association of the lev-
els of IL-18 and the pathogenesis of HIV-1 infection. 
Several studies have examined the association of SNPs 
in the IL-18 gene with various other diseases [23,24], 
but that with the HIV-1 infection has not been fully 
explored. For this reason, we have evaluated the as-
sociation of the IL-18 gene promoter polymorphism 
–607C>A with the HIV-1/AIDS infections. To the best 
of our knowledge, this is the first association study of 
the IL-18 gene polymorphism in North Indian HIV-1/
AIDS patients.
MATERIALS AND METHODS
In this case control study 500 patients with HIV-1/ 
AIDS and an equal number of sex- and age-matched 
control groups were recruited from the Department of 
Internal Medicine, Post-Graduate Institute of Medical 
Education and Research at Chandigarh, India. Cases 
and controls were from the same geographical area 
and same ethnic backgrounds. Of the 500 cases, 174 
were females and 326 males with a mean age of 35.4 
± 7.9, while of the 500 controls, 183 were females and 
317 males with a mean age of 36.2 ± 9.8 years.
The research protocols were reviewed and ap-
proved by the ethics committee of the institute. Written 
informed consent was obtained from all the participat-
ing individuals. Information about age, sex, occupa-
tion and other relevant clinical data was gathered from 
the immunological cards of the HIV-1/AIDS patients. 
Peripheral blood (2-3 mL) was drawn and collected in 
an EDTA-coated tube for genomic DNA extraction. 
The samples were kept at –80°C until used for DNA 
isolation. Genomic DNA was extracted from periph-
eral blood leukocytes by sodium dodecyl sulphate ly-
sis and proteinase K digestion followed by standard 
phenol-chloroform methods as previously described 
[15] and the extracts were subjected to a polymerase 
chain reaction (PCR).
Genotyping of the IL-18 –607C>A SNP was per-
formed by (sequence specific primer)-SSP-PCR anal-
ysis [14]. Briefly, a common reverse primer 5’-TAA 
CCT CAT TCA GGA CTT CC-3’ and two sequence 
specific forward primers 5’-GTT GCA GAA AGT 
GTA AAA ATT ATT AC-3’ and 5’-GTT GCA GAA 
AGT GTA AAA ATT ATT AA-3’ were used. An ampli-
fication product of 196 bp was detected. A control for-
ward primer 5’-CTT TGC TAT CAT TCC AGG AA-3’ 
was used to amplify a 301 bp fragment covering the 
polymorphic site as an internal positive amplification 
control.
The reaction was performed in a final volume of 
25 µL consisting of 2.5 µL of 10X PCR buffer, 0.25 µL 
of 10 mmol of dNTP, 1.5 µL of 25 mM MgCl2, 2 µL of 
genomic DNA, and 0.5 U of Taq polymerase. For every 
reaction mixture, 0.5 µL of the –607C allele-specific or 
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the –607A allele-specific forward primer and 0.5 µL of 
the common reverse primer were included. The 0.15 
µL of internal positive control primer was added to re-
action mixture. The PCR products (Figure 1) were vi-
sualized by ethidium bromide stained electrophoresis 
on 2% agarose gel. Two separate PCRs were carried 
out for every individual DNA sample.
Reactions were carried out in a Bio-Rad MyCycler 
(Bio-Rad Laboratories, Hercules, CA, USA). Denatur-
ation for 2 min. at 94°C was performed as the first step. 
This was followed by seven cycles of 20 seconds at 
94°C, 40 seconds at 64°C and 40 seconds at 72°C and 
25 cycles of 20 seconds at 94°C, 40 seconds at 57°C 
and 40 seconds at 72°C. All PCR products were visual-
ized under UV light on ethidium bromide-stained 2% 
agarose gels.
Statistical analysis. Results were analyzed with 
SPSS software, version 11 for windows 5 (SPSS Inc., 
Chicago, IL, USA). Hardy-Weinberg equilibrium be-
tween observed and expected genotype distributions 
was determined by means of the Pearson Chi-square 
(χ2) test. For the assessment of risk factors, ORs with 
95% CIs were calculated according to Epi Info Ver-
sion 3.5.1 2008; Centers for Disease Control and Pre-
vention (CDC), Atlanta, GA, USA. The frequencies 
of genotypes and alleles were calculated by manual 
counting. The Pearson χ2 test was used to calculate 
the significance of the differences in frequency of 
genotypes and alleles between the patients and control 
subjects. p Values of <0.05 were considered to be sta-
tistically significant.
RESULTS
The demographic profile of HIV-1/AIDS patients 
and healthy controls in the study group is summarized 
in Table 1. Regarding gender distribution, there was no 
significant difference between cases and controls. It was 
found that the proportion of males was 65.2 and 63.4% 
in cases and controls, respectively, whereas for females 
it was 34.8 and 36.6% in cases and controls, respective-
ly. The mean age [± standard deviation (SD) in years] 
was 35.4 ± 7.9 years for cases and 36.2 ± 9.8 years for 
controls. There was no significant mean age difference 
between the cases and the controls (p = 0.180).
Staging of HIV infection was done by the phy-
sicians as per the World Health Organization (WHO) 
staging guidelines. Accordingly, all the four stages 
of HIV/AIDS were found in the cases. Of all the 500 
seropositive cases, 74 (14.85%) were at stage I, 143 
(28.6%) at stage II, 113 (22.6%) at stage III and 170 
(34%) were at stage IV (AIDS) of the disease. The 
mean counts of CD4+-T cells at stages I, II, III, and IV 
were 331, 268, 206, and 113, respectively.
In all, 500 HIV-1/AIDS patients and an equal 
number of controls were studied for –607C>A IL-18 
promoter polymorphism. As shown in Figure 1, there 
were C/C, C/A and A/A genotypes at position –607. 
The PCR products of homozygous individuals showed 
a 301 bp DNA segment and those of heterozygous in-
dividuals showed 196 and 301 bp fragments.
The genotypic distributions and allelic frequencies 
of –607C>A are presented in Table 2. The genotype 
distributions are in agreement with Hardy-Weinberg 
equilibrium. A significant increase in frequency of the 
wild C/C genotype was observed in patients when com-
pared to control subjects (43.0 vs. 38.4%, p = 0.040). 
The frequency of the C/A genotype was slightly higher 
in controls (52.8%) than in cases (51.4%) (p = 0.321) 
and that of the A/A genotype was significantly lower 
(p = 0.040) in patients (5.6%) than in controls (8.8%). 
The frequencies of the C and A alleles were 68.7 and 
31.3% in cases and 64.8 and 35.2% in controls (p = 
0.071), respectively.
For accounting of the risk assessment the geno-
typic data was analyzed with Epi Info software. The 
results showed a significantly reduced risk of HIV-1 
infection with the homozygous variant –607A>A gen-
otype when it was computed against healthy controls 
Figure 1. A 2% agarose gel electrophoresis of PCR prod-
ucts of the IL-18 gene at the position –607C>A. 
The 301 bp bands represent the PCR internal 
control amplified using the forward control 
primer and the common reverse primer. The 196 
bp bands represents the PCR amplification prod-
ucts of the alleles C and A amplified using the 
sequence specific primers with the common re-
verse primers. M: 100 bp DNA marker; lanes 1A 
and 1B: wild CC genotype; lanes 2A and 2B: CA 
genotype, and lanes 3A and 3B: AA genotype.
301 bp
196 bp
M    1A    1B     2A     2B    3A    3B      M
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[odds ratio (OR) = 0.57, 95% confidence interval (95% 
CI) = 0.33-0.98, p = 0.040]).Conversely, a statistically 
insignificant reduced risk of HIV-1 infection was ob-
served with the heterozygous –607C>A genotype (OR 
= 0.87, 95% CI = 0.66-1.14, p = 0.321). Likewise, a 
statistically insignificant association of HIV-1 infec-
tion was observed with the –607A allele (OR = 0.84, 
95% CI = 0.69-1.01, p = 0.071).
The genotypic and allelic frequencies of –607C>A 
between only seropositive for HIV-1 and seropositive 
patients with disease are presented in Table 3. Of the 
500 seropositive patients with HIV-1, 330 (66%) were 
patients at stages I-III without AIDS and the remaining 
170 (34%) were at the AIDS stage. The frequency of 
the wild C/C genotype in seropositive patients without 
AIDS disease was 130 (26%) as compared to 85 (17%) 
Table 1.  Demographic information on patients and controls.
Parameters HIV-1/AIDS Patients
(n = 500)
Healthy Controls
(n = 500)
p Value
Gender : n (%)
$  Males
$  Females
326 (65.2)
174 (34.8)
317 (63.4)
183 (36.6)
0.553
Age (years) mean ± SD 35.39 ± 7.90 36.15 ± 9.75 0.180
Table 2. Genotype and allele distribution of IL-18 gene in patients and controls.
IL-18 –607(C/A) Patients (n = 500) Controls (n = 500) OR (95% CI) p Value
Genotype n (%) n (%)
CC 215 (43.0) 192 (38.4) 1.0 Reference
CA 257 (51.4) 264 (52.8) 0.87 (0.66-1.14) 0.321
AA 28 (5.6) 44 (8.8) 0.57 (0.33-0.98) 0.040
Allelic
C allele 687 (68.7) 648 (64.8) 1.0 Reference
A allele 313 (31.3) 352 (35.2) 0.84 (0.69-1.01) 0.071
OR: odds ratio [OR was calculated by Epi-info Version 3.5.1. (Centers for Disease Control and Prevention, Atlanta, GA, USA); 95% 
CI: 95% confidence interval; a p value of ≤0.05 was considered significant.
Table 3. Genotype and allele distribution of the IL-18 gene in HIV-1 seropositive patients.
Genotype HIV-1 Patients
With AIDSa
(n = 170)
HIV-1 Patients
Without AIDsa
(n = 330)
OR (95% CI) p Value
CC 85 130 1.0 Reference
CA 79 178 0.68 (0.46-1.01) 0.057
AA 6 22 0.42 (0.14-1.14) 0.098
C 249 438 1.0 Reference
A 91 222 0.72 (0.53-0.97) 0.031
a Staging of HIV/AIDS was done by the physicians as per the World Health Organization (WHO) clinical staging of HIV disease in 
adults and adolescents.
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in HIV-1 patients at at the AIDS stage. The frequency 
of the heterozygous C/A genotype was 178 (35.6%) 
and 79 (15.8%) for seropositive patients without AIDS 
and those at the AIDS stage, respectively. The fre-
quency of the mutant genotype A/A was 4.4% (22) in 
HIV-1 patients without AIDS disease and 1.2% (six) 
in patients with AIDS. A statistically insignificant re-
duced risk of HIV infection was observed with the C/A 
genotype of IL-18-607 (OR = 0.68, 95% CI = 0.47-
1.01, p = 0.057). Moreover, a statistically insignificant 
reduced risk of HIV infection was observed with the 
homozygous variant A/A genotype (OR = 0.42, 95% 
CI = 0.14-1.14, p = 0.098).
DISCUSSION
Cytokines are important immunomodulatory mol-
ecules in immune response against pathogenic micro-
organisms and also have an important role in the setting 
of disorders affecting the immune system. Cytokine 
genes are highly polymorphic and genetic variations 
that can alter the expression of cytokine genes could 
have evident pathological consequences, potentially 
leading to a number of chronic diseases, increased 
risk of infection, and altered outcome of acute disor-
ders [8,10]. With regard to HIV-1, cytokines have been 
identified as important tools toward better understand-
ing of the profound interactions occurring between 
HIV-1 and the human immune system. Moreover, cy-
tokine genes have been implicated to influence the rate 
of disease progression in HIV-1 seropositive patients 
either positively or negatively [6,7,26,27].
Interleukin-18 is a pleiotropic proinflammatory 
cytokine that is recognized as an important regula-
tor of innate and acquired immune responses [28]. It 
is mainly produced by monocytes/macrophages and 
many other immune and non immune cells [17,29]. By 
virtue of its nature, IL-18 plays a key role in induction 
of both Th1 and Th2 cytokines and, thereby, modu-
lates their immune responses. Interleukin-18 possesses 
broad and potent immunomodulatory properties. It 
is therefore not surprising that it appears essential to 
host defenses against a variety of infections. The in-
volvement of IL-18 has been identified in several in-
flammatory and autoimmune diseases, in a variety of 
cancers, and in the context of numerous infectious dis-
eases [16,17]. Furthermore, it has been reported that 
IL-18 is not only one of several inflammatory markers 
that increases during HIV-1 infection, but may also be 
involved in the immunopathogenesis of this disease 
[22].
The expression of the IL-18 gene seems to be reg-
ulated at the transcriptional level by the two SNPs at 
positions –607C>A and –137G>C in the promoter of 
this gene. The C>A substitution at position –607 dis-
rupts the binding site of a potential cAMP-responsive 
element binding protein and the G>C substitution at 
position –137 abolishes the H4TF-1 nuclear factor-
binding site. The –607C and –137G alleles have been 
associated with higher transcription activity than the 
–607A and –137C alleles, respectively [15]. Moreover, 
investigations carried out to determine the association 
of SNPs in the IL-18 gene and various types of dis-
eases have also shown the influence of the –607C/A 
promoter polymorphism on quantitative expression of 
the IL-18 protein. According to these studies, subjects 
with –607C/C and C/A genotypes have had signifi-
cantly higher IL-18 concentrations than those with the 
–607A/A genotype [23,24].
Taking into account the findings of Giedraitis 
et al. [15], Sakai et al. [23] and Xu et al. [24], 500 
HIV-1 patients and an equal number of healthy con-
trol subjects were studied for the IL-18 –607C>A gene 
promoter polymorphism to assess its possible associa-
tion with the risk of HIV-1 infection. Analysis of the 
present data demonstrated an association between the 
IL-18 –607C/A polymorphism and risk of HIV-1 in-
fection in North Indians. In the present study, statisti-
cally significant reduced risk of HIV-1 infection was 
observed with the –607A/A genotype, as compared to 
healthy controls (OR = 0.57, 95% CI = 0.33-0.98, p = 
0.040). On the other hand, a statistically insignificant 
reduced risk of HIV-1 infection was observed with the 
heterozygous –607C/A genotype (OR = 0.87, 95% CI 
= 0.66-1.14, p = 0.321).
As to the effect on HIV-1 infection, increased IL-
18 concentrations in HIV-1 patients are likely to play 
an important role in the disease progression and re-
lated clinical conditions [30]. Interleukin-18 has also 
been shown to induce HIV-1 replication in acutely 
or chronically infected human monocytic and T cell 
lines, suggesting its pathogenic role in HIV-1 patho-
genesis [18,19,31]. Furthermore, Stylianou et al. [22] 
suggested the involvement of IL-18 in augmenting 
the expression of the HIV-1 co-receptor CXCR4 in 
peripheral blood monocytic cells (PBMCs) from HIV-
1-infected patients. Such up-regulation of CXCR4 by 
IL-18 seems to facilitate viral entry and replication, 
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indicating a further role of the cytokine in the disease 
progression. Moreover, Wiercinska-Drapalo et al. [21] 
demonstrated the presence of an association between 
plasma level of IL-18 with viral load and disease pro-
gression in HIV-1-infected patients. In another in-
stance, Song et al. [32] demonstrated the presence of 
overall positive correlation between serum IL-18 and 
HIV-1 viral load accompanied by negative correlation 
between serum IL-18 and CD4+-T cell count.
The allelic variants of the IL-18 gene –607C>A 
promoter polymorphism have been shown to influence 
the transcriptional activity and subsequently a level of 
IL-18 production. The IL-18 –607C/C and C/A geno-
types represent the potential to produce high levels of 
IL-18, while, the A/A genotype is associated with low 
transcription activity and low production of this proin-
flammatory cytokine [23,24]. In connection with HIV-
1/AIDS, Segat et al. [33] demonstrated the association 
between the IL-18 gene –607C>A promoter poly-
morphism and risk of HIV-1 infection in seropositive 
Brazilian children. Moreover, high concentrations of 
circulating IL-18 have been correlated with enhanced 
HIV-1 replication and accelerated progression of the 
HIV-1 infection towards AIDS [21,30].
The results of the current study revealed the oc-
currence of the –607 A/A genotype at statistically 
significant lower frequency in the HIV-1 patients 
than healthy controls (p = 0.040). This suggests that 
subjects possessing the –607 A/A genotype may be at 
reduced risk of HIV-1 infection. Furthermore, the ex-
istence of the A allele in the heterozygous –607 C/A 
genotype may also confer reduced risk against disease 
progression. However, as the IL-18 gene –607 C>A 
promoter polymorphism was the only SNP examined 
in this study, we cannot rule out the possibility that 
genetic variants from other promoter positions of this 
gene may also be participating in disease progression 
of HIV-1 infection.
The findings of the present study provide addi-
tional evidence regarding the possible involvement of 
host genetic variations in the immunopathogenesis of 
HIV-1 infection. It was found that the –607 A allele 
in the promoter of IL-18 gene may be playing a pro-
tective role against the progression of HIV-1 infection 
to AIDS. The –607 A allele is assumed to results in 
attenuated transcription activity and lower IL-18 cy-
tokine production that in turn may be involved in slow-
ing down viral replication. As a result, HIV-1 patients 
with the –607 A/A and C/A genotypes may progress to 
AIDS at slower rate than those with the C/C genotype. 
However, the results of this study need to be further 
evaluated by undertaking investigations correlating 
IL-18 gene promoter polymorphisms with serum lev-
els of IL-18 in HIV-1/AIDS patients for precise deter-
mination of the role IL-18 plays in HIV-1 infection. 
Likewise, how the –607 A allele interacts with other 
possible genetic factors in influencing the pathogen-
esis of HIV-1 infection requires further study.
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